NASDAQ:IPA
Immunoprecise Antibodies Ltd. Stock News
$1.00
+0.0094 (+0.95%)
At Close: Jun 25, 2024
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, tod
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
07:00am, Wednesday, 12'th Jun 2024
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic rese
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic rese
IPA's Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
07:00am, Tuesday, 04'th Jun 2024
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research
VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already
VICTORIA, BC / ACCESSWIRE/ April 12, 2024 / InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability and speed challenge
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), InterSystems, a creative data technology provider dedicate
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
07:02am, Wednesday, 20'th Mar 2024
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research
ImmunoPrecise Antibodies Ltd. (IPA) Q3 2024 Earnings Call Transcript
02:49pm, Thursday, 14'th Mar 2024
ImmunoPrecise Antibodies Ltd. (IPA) Q3 2024 Earnings Call Transcript
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates
10:30am, Thursday, 14'th Mar 2024
ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate.
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
08:05am, Thursday, 14'th Mar 2024
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research
VICTORIA, BC / ACCESSWIRE / March 8, 2024 / Anyone familiar with the intricacies of life science knows how truly complicated DNA is; without a full understanding of the language of DNA, scientists are
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
08:01am, Monday, 04'th Mar 2024
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research
ImmunoPrecise Antibodies (NASDAQ:IPA) Is Changing How We Look At The Complex World Of Antibody Discovery
08:35am, Tuesday, 13'th Feb 2024
VICTORIA, BC / ACCESSWIRE / February 13, 2024 / Even though we speak, listen, read and write every day, language is incredibly complex and ever-evolving. Context is critical to understanding.
